Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (36): 6701-6704.doi: 10.3969/j.issn.1673-8225.2011.36.012

Previous Articles     Next Articles

Umbilical cord mesenchymal stem cells effect on inflammatory responses of rats with type Ⅱ collagen-induced arthritis

Li Hui1, Gu Jian2, Lin Chuan-ming2, Ma Li2, Shen Lian-jun2, Wu Wei2, Wang Zhong-qiang2   

  1. 1Clinical Medical College of Yangzhou University, Yangzhou  225001, Jiangsu Province, China
    2Institute of Hematology of Yangzhou, Clinical Medical College of Yangzhou University, Yangzhou  225001, Jiangsu Province, China
  • Received:2011-03-06 Revised:2011-04-11 Online:2011-09-03 Published:2011-09-03
  • Contact: Gu Jian, Professor, Chief physician, Institute of Hematology of Yangzhou, Clinical Medical College of Yangzhou University, Yangzhou 225001, Jiangsu Province, China maolujiu918@yahoo.com.cn
  • About author:Li Hui★, Master, Clinical Medical College of Yangzhou University, Yangzhou 225001, Jiangsu Province, China lh99beautiful@126.com
  • Supported by:

    the Health Bureau of Jiangsu Province, No. 201048*

PDF

433

Abstract:

BACKGROUND: Umbilical cord mesenchymal stem cells (UC-MSCs) can express various kinds of embryonic stem cell-specific molecular markers, and be characterized as good differentiation potential, strong proliferative capacity, and low immunogenicity.
OBJECTIVE: To observe the interventional effect of UC-MSCs on immune inflammatory pathological process of rheumatoid arthritis. 
METHODS: CIA rat models were established and divided into three groups. At 4 weeks after modeling, UC-MSCs were injected via the tail vein in the UC-MSCs group, and normal saline was injected in the model group.
RESULTS AND CONCLUSION: The levels of interleukin-1 (IL-1), IL-6, IL-18, tumor necrosis factor alpha, vascular cell adhesion molecule and neutrophil cell surface expression of CD11b were higher in the model group than the normal group (P < 0.05) at 7 and 35 days after treatment. Those factor levels in the UC-MSCs group were significantly lower than those in the model group after treatment (P < 0.05), those at 7 days were higher than at 35 days (P  < 0.05). UC-MSCs can obviously inhibit the release of inflammatory cytokines and abnormal activation of endothelial cells, and relieve immune and inflammatory reactions of rheumatiod arthritis.

CLC Number: